The CHK1 inhibitor SRA737 synergizes with PARP1 inhibitors to kill carcinoma cells

Inhibitors of PARP1 are approved therapeutic agents in ovarian carcinomas. We determined whether the novel clinically relevant CHK1 inhibitor SRA737 interacted with PARP1 inhibitors to kill carcinoma cells. In multiple mammary and ovarian cancer lines SRA737 synergized with the PARP1 inhibitors olap...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer Biol Ther
Hlavní autoři: Booth, Laurence, Roberts, Jane, Poklepovic, Andrew, Dent, Paul
Médium: Artigo
Jazyk:Inglês
Vydáno: Taylor & Francis 2018
Témata:
Research Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6154848/
https://ncbi.nlm.nih.gov/pubmed/30024813
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2018.1472189
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky